Rocket Pharmaceuticals, Inc.
RCKT
Positions held
Your positionsRCKT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $288.71M | Enterprise value | $29.76M | Trailing P/E | — | Forward P/E | -2.02 |
| PEG | — | Price / book | 0.78 | Beta | 0.50 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -4.8% | ROA | -28.4% | Debt / equity | 0.07 |
| Current ratio | 9.25 | Free cash flow | $86.14M | Analyst recommendation | buy | Mean target | $8.58 |
| 52w high | $5.45 | 52w low | $2.42 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | $123M | -$47.6M | -$42.5M | -$50.3M | -$68.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$46.9M | -$48.5M | -$44.0M | -$52.4M | -$67.7M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$223M | -$259M | -$246M | -$222M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$229M | -$273M | -$260M | -$224M | — |
Headlines — positive tone
• [OK · fundamentals] Rocket Pharmaceuticals Shares Rise After Goldman Sachs Upgrade
• [OK · fundamentals] Rocket Pharmaceuticals Shares Rise After Needham Upgrade
News
2026-10-08 · Rocket Pharmaceuticals Shares Rise After Goldman Sachs Upgrade
2026-10-08 · Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral From Sell, Price Target is $4
2026-10-07 · Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
2026-10-07 · MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high
2026-10-07 · Rocket receives $150m credit facility to advance cardiovascular portfolio
2026-10-07 · Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
2026-10-06 · Rocket Secures Credit Facility From Hercules Capital
2026-10-06 · Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
2026-09-22 · Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?
2026-09-18 · Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
2026-09-16 · Rocket Pharmaceuticals Shares Rise After Needham Upgrade
Price (daily)
Full chart · RSI · MACD · patterns